Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hamostaseologie·2018
Same author

Hämostaseologie--Progress in Haemostasis. GTH is moving to a European scientific society.

Hamostaseologie·2016
Same author

Platelet pathology and antiplatelet strategies. Resolved and unresolved issues.

Hamostaseologie·2016
Same author

Associations between thrombophilic risk factors and determinants of atherosclerosis and inflammation in patients with non-arteritic anterior ischaemic optic neuropathy.

Hamostaseologie·2016
Same author

Coagulation disorders - recent lessons from clinical conditions.

Hamostaseologie·2015
Same author

[The ambivalence of progress - do we need a less-is-more strategy?**. **Extract from the programmtic opening speech delivered at the 59th Annual GTH Congress 2015].

Hamostaseologie·2015
Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026
Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

[Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, clinical management].

R E Scharf1

  • 1Institut für Experimentelle und Klinische Hämostaseologie, Hämotherapie und Transfusionsmedizin, Universitätsklinikum Düsseldorf, Biologisch-Medizinisches Forschungszentrum der Heinrich-Heine-Universität, Düsseldorf. rscharf@uni-duesseldorf.de

Hamostaseologie
|January 10, 2009
PubMed
Summary
This summary is machine-generated.

Drugs are the most common cause of acquired platelet dysfunction, affecting platelet function and potentially causing bleeding. Various medications and clinical conditions contribute to these frequent, heterogeneous defects.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Context:

  • High consumption of pharmacological agents in Western societies.
  • Platelet dysfunction is a significant clinical concern.
  • Acquired platelet disorders are more prevalent than inherited ones.

Purpose:

  • To highlight acquired platelet function disorders as a frequent clinical issue.
  • To discuss the diverse causes and pathogenesis of acquired platelet dysfunction.
  • To classify and review these disorders based on clinical settings.

Summary:

  • Pharmacological agents, including antiplatelet drugs (e.g., aspirin, clopidogrel, GPIIb-IIIa antagonists) and other common medications (NSAIDs, antibiotics, SSRIs, volume expanders), are primary causes of acquired platelet dysfunction.
  • Beyond drugs, various clinical conditions can lead to qualitative platelet disorders and bleeding diathesis.
  • Acquired platelet function defects are heterogeneous, can occur at any age, and range from mild to life-threatening, necessitating classification by underlying cause.

Impact:

  • Enhances understanding of common causes of bleeding diathesis.
  • Provides a framework for diagnosing and managing acquired platelet dysfunction.
  • Emphasizes the clinical significance of drug-induced and condition-associated platelet defects.